Ocuphire Pharma Investor Day Presentation Deck

Broad Opportunities to Treat Retinal Diseases with APX Platform DME APX3330 May Treat Patients Across Retinal Diseases as Single Agent or Adjunctive Therapy DR 36 ● ● ● ● Potential Differentiated Solution Potential First Oral Rx for Retina Diseases First-line earlier intervention for the diabetic eye Add-on therapy to current anti-VEGF treatments to reduce intravitreal injection burden Proven Novel Mechanism May decrease both inflammation and angiogenesis Convenient Daily Regimen - - Favorable Oral Safety Profile As seen in 11 completed Phase 1 and Phase 2 clinical trials Improve Patient Compliance Potentially alleviate the frequent burden of injections - DR DME Wet AMD Dry AMD RVO GA Inflammatory component is common across these retina indications and potentially addressable by the MOA of Ref-1 APX3330 Current anti-VEGF treatments APX2009 APX2014 APX3330 (Local Delivery) Ocuphire PHARMA

View entire presentation